Few HPV tests can track genotype-specific high-risk HPV persistence, beyond HPV 16 and HPV 18.
The BD Onclarity™ HPV Assay can track genotype-specific HPV persistence for the most high-risk HPV genotypes, as compared to other FDA-approved HPV tests.1,2
Why does HPV type, or genotype, persistence matter?
The persistence of infection with the same high-risk HPV genotype is the most important determinant of cervical cancer risk in women who test HPV positive – regardless of the HPV genotype. An infection with a different HPV genotype is called a type switch and doesn’t cause such a risk.3-7
This means that identifying the specific HPV type causing her infection each time she is tested is key to identifying your patients at most risk for developing cervical disease – and the more genotypes you can identify, the more actionable information you have.
How do you track HPV persistence?
Most HPV tests have partial genotyping, which means that they cannot identify which HPV genotype is causing the infection beyond HPV 16 and 18 because other genotypes are reported in a single pooled result.2,3
Tracking a persistent HPV infection beyond HPV 16 and 18 is only possible with the BD Onclarity™ HPV Assay thanks to the extended genotyping information that it provides.1-3
The BD Onclarity™ HPV Assay individually identifies 6 HPV genotypes with the highest risk for disease
From one HPV test to the next, it is possible to know if there is a genotype-specific persistent infection, if there was a type switch or if the HPV infection was cleared.3,7
ARE YOU PAYING ATTENTION TO GENOTYPE-SPECIFIC HPV PERSISTENCE?
*As compared to other FDA-approved HPV tests.
FDA, Food and Drug Administration; HPV, human papillomavirus.
1. BD OnclarityTM HPV Assay US Package Insert [8089894].
2. Salazar KL et al. J Am Soc Cytopathol. 2019;8(5):284–92.
3. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1–13.
4. Elfgren et al. Am J Obstet Gynecol. 2017;216:264.e1-7.
5. Radley D et al. Hum Vaccin Immunother. 2016;12(3):768–72.
6. Bodily J, Laimins LA. Trends Microbiol. 2011;19(1):33–9.
7. Bonde JH et al. J Low Genit Tract Dis. 2021;25(1):27–37.
Learn more about our BD Women’s Health solutions
This form is only intended for use by healthcare professionals seeking additional information about BD products and solutions. Patients seeking health and treatment information should contact their healthcare professional and can find additional resources from ACOG and the American Cancer Society.
Do not submit protected health information (PHI) or patient information (PII) through this form. If you do submit PHI or PII, your question may not be answered, as the information will be deleted to protect your privacy.